We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

152 hedge funds and large institutions have $1.68B invested in Agios Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 63 increasing their positions, 50 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 50

24% more capital invested

Capital invested by funds: $1.36B → $1.68B (+$325M)

0.36% more ownership

Funds ownership: 106.45% → 106.81% (+0.36%)

7% less funds holding

Funds holding: 163 → 152 (-11)

45% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 22

56% less call options, than puts

Call options by funds: $5.2M | Put options by funds: $11.9M

Holders
152
Holders Change
-11
Holders Change %
-6.75%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
63
Reduced
50
Closed
22
Calls
$5.2M
Puts
$11.9M
Net Calls
-$6.72M
Net Calls Change
-$2.9M

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$32.2M
2
FCM
Farallon Capital Management
California
+$14.8M
3
First Trust Advisors
First Trust Advisors
Illinois
+$8.04M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$4.64M
5
Macquarie Group
Macquarie Group
Australia
+$4.47M

Top Sellers

1
State Street
State Street
Massachusetts
-$12M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$11.7M
3
N
Nuveen
North Carolina
-$5.11M
4
AC
Armistice Capital
New York
-$5.08M
5
IHAM
Integral Health Asset Management
New York
-$4.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$166M +$3.55M +142,497 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$156M +$2.38M +95,660 +2%
BlackRock
3
BlackRock
New York
$134M -$2.26M -90,801 -2%
BG
4
Bellevue Group
Switzerland
$114M – – –
AC
5
Armistice Capital
New York
$92.2M -$5.08M -204,000 -6%
FCM
6
Farallon Capital Management
California
$76.1M +$14.8M +596,000 +28%
RSCM
7
Rock Springs Capital Management
Maryland
$76.1M +$611K +24,562 +0.9%
State Street
8
State Street
Massachusetts
$73.1M -$12M -482,533 -16%
JP Morgan Chase
9
JP Morgan Chase
New York
$70.6M +$32.2M +1,294,462 +108%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$64.1M +$4.29M +172,467 +8%
First Trust Advisors
11
First Trust Advisors
Illinois
$61.2M +$8.04M +322,959 +18%
EAM
12
Erste Asset Management
Austria
$47.9M – – –
Macquarie Group
13
Macquarie Group
Australia
$46.1M +$4.47M +179,572 +12%
ACH
14
ArrowMark Colorado Holdings
Colorado
$44.6M +$387K +15,549 +1%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$36.6M +$739K +29,695 +2%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$32.8M +$1.7M +68,308 +6%
T. Rowe Price Investment Management
17
T. Rowe Price Investment Management
Maryland
$26.3M -$926K -37,200 -4%
BNP Paribas Asset Management
18
BNP Paribas Asset Management
France
$26.3M -$2.45M -98,328 -10%
PAMS
19
Pictet Asset Management (Switzerland)
Switzerland
$25M +$4.64M +186,326 +27%
Fisher Asset Management
20
Fisher Asset Management
Washington
$24.7M +$514K +20,667 +2%
Goldman Sachs
21
Goldman Sachs
New York
$22.6M -$4.09M -164,550 -17%
Northern Trust
22
Northern Trust
Illinois
$20.1M +$881K +35,399 +5%
Deutsche Bank
23
Deutsche Bank
Germany
$16.4M -$299K -11,996 -2%
SCM
24
Suvretta Capital Management
New York
$12.9M – – –
Charles Schwab
25
Charles Schwab
California
$12.4M +$186K +7,463 +2%
1
2 3 4 5

AGIO Hedge Fund Activity: Q2 2023 in Review

152 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2023, worth a combined $1.68B — up 24% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of AGIO and 12 opened new positions — a net loss of 10 holders — while 50 trimmed existing stakes and 63 added.

The largest buyer was JP Morgan Chase, adding an estimated $32.2M. The largest seller was State Street, cutting an estimated $12M.

  • 152 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2023, down from 163 in Q1 2023.
  • Funds reported $1.68B of Agios Pharmaceuticals stock for Q2 2023, up 24% quarter-over-quarter.
  • 12 funds opened new Agios Pharmaceuticals positions in Q2 2023 and 22 closed out, a net change of -10 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2023 was JP Morgan Chase, an estimated $32.2M added.
  • The largest Agios Pharmaceuticals seller in Q2 2023 was State Street, an estimated $12M sold.

Based on aggregated 13F filings for Q2 2023.